Quarterly and monthly dosing, with the option to switch1 to suit your patients' needs

When switching dosing regimens, the first dose of the new regimen should be administered on the next scheduled
dosing date of the prior regimen1

The treatment benefit should be assessed within three months after initiation of treatment. Evaluation of the need
to continue treatment is recommended regularly thereafter1

*Results from a survey of patients who completed the HALO LT study. Patients in the HALO LT were randomised to
either quarterly or monthly dosing. Patients were blinded to the dosing regimen that they were receiving.
253 patients completed the survey.2

Suggestions to explore next

Significantly more migraine-free days vs placebo1,3-6

Efficacy of AJOVY®

Flexibility to help meet your patients' needs1,6

FLEXIBILITY OF AJOVY®

A generally well-tolerated treatment choice1,3-6

SAFETY PROFILE FOR AJOVY®